SCHEMBL275988

SCHEMBL275988

COCC(=O)N1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 1/20 0.51
TPSD1 Q9BZJ3 1/20 0.51
TPSG1 Q9NRR2 1/20 0.51
ALDH1A1 P00352 5/20 0.45
CA2 P00918 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
CYP1A2 P05177 2/20 0.43
CHKA P35790 1/20 0.42
MAPT P10636 1/20 0.42
CYP2D6 P10635 7/20 0.41
CYP3A4 P08684 6/20 0.41
CYP2C9 P11712 2/20 0.41
TSHR P16473 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
CHRNB3 Q05901 1/20 0.41
CHRNA6 Q15825 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18167985 0.98 TPSAB1 (0.50) TPSAB1TPSD1TPSG1ALDH1A1CA2
Hydrochloric Acid SCHEMBL18824267 0.91 TPSAB1 (0.45) TPSAB1TPSD1TPSG1ALDH1A1CA2
SCHEMBL10618753 0.88 TPSAB1 (0.41) TPSAB1TPSD1TPSG1ALDH1A1CA2
Trifluoroacetic Acid SCHEMBL28290467 0.88 PKM (0.49) TPSAB1TPSD1TPSG1ALDH1A1CYP1A2
SCHEMBL8402970 0.84 ALDH1A1 (0.51) ALDH1A1CYP1A2MAPTCYP2D6CYP3A4
SCHEMBL14010813 0.84
Tert-Butyl Formate SCHEMBL28290495 0.84 TPSAB1 (0.43) TPSAB1TPSD1TPSG1ALDH1A1CYP1A2
SCHEMBL16826963 0.82 TPSAB1 (0.44) TPSAB1TPSD1TPSG1ALDH1A1CA2
SCHEMBL944668 0.80 ALDH1A1 (0.53) ALDH1A1CYP1A2MAPTTSHRL3MBTL1
SCHEMBL11406691 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 US disclosed
EP-3601297-B9 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC (US) 2023-05-24 EP disclosed
US-20230029385-A1 2-METHYL-AZA-QUINAZOLINES BAYER AG (DE) 2023-01-26 US disclosed
EP-4055013-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2022-09-14 EP disclosed
EP-3283482-B1 PLK4 INHIBITORS LUDWIG INST FOR CANCER RES LTD (CH) 2022-04-06 EP disclosed
US-11274083-B2 Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents SYNGENTA CROP PROTECTION AG (CH) 2022-03-15 US disclosed
EP-3728235-B1 SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS SYNGENTA CROP PROTECTION AG (CH) 2022-02-09 EP disclosed
US-11224601-B1 Compounds that inhibits MCL-1 protein AMGEN INC. (US) 2022-01-18 US disclosed
US-20210087151-A1 SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS SYNGENTA CROP PROTECTION AG (CH) 2021-03-25 US disclosed
US-10300075-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2019-05-28 US disclosed
EP-0447013-B1 Fluorobenzene sulphonamides SCHERING AG (DE) 1994-08-03 EP disclosed
US-5284647-A Administering for magnetic resonance imaging SCHERING AKTIENGESELLSCHAFT (DE) 1994-02-08 US disclosed
US-5210290-A NMR diagnostic aid SCHERING AKTIENGESELLSCHAFT (DE) 1993-05-11 US disclosed
EP-0263059-B1 COMPLEXES AMIDES SCHERING AKTIENGESELLSCHAFT (DE) 1992-11-11 EP disclosed
EP-0447013-A1 Fluorobenzene sulphonamides SCHERING AKTIENGESELLSCHAFT (DE) 1991-09-18 EP disclosed
EP-0413405-A2 Use of amide complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1991-02-20 EP disclosed
EP-0336879-A1 Meso-tetraphenylporphyrin complex compounds,process for their preparation and pharmaceuticals containing them SCHERING AKTIENGESELLSCHAFT (DE) 1989-10-11 EP disclosed
EP-0263059-A2 Complexes amides SCHERING AKTIENGESELLSCHAFT (DE) 1988-04-06 EP disclosed
EP-0255471-A1 1,4,7,10-Tetraazacyclododecane-derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1988-02-03 EP disclosed
EP-0250358-A2 Novel complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1987-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274083-B2 Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents UNG, TYMP, TYMS TPSAB1 4036/4885TPSD1 2452/4885TPSG1 2914/4885
US-20210087151-A1 SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS UNG, TYMP, TYMS TPSAB1 4036/4885TPSD1 2452/4885TPSG1 2914/4885
US-20230029385-A1 2-METHYL-AZA-QUINAZOLINES AZI2, DNMT1, TPMT TPSAB1 3454/4885TPSD1 3267/4885TPSG1 3212/4885
US-10300075-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 TPSAB1 3695/4885TPSD1 4525/4885TPSG1 4445/4885
US-11773068-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A TPSAB1 3667/4885TPSD1 3526/4885TPSG1 2673/4885
US-11224601-B1 Compounds that inhibits MCL-1 protein MCL1, BCL9, BCL2L1 TPSAB1 3748/4885TPSD1 4541/4885TPSG1 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.